<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04329390</url>
  </required_header>
  <id_info>
    <org_study_id>MAC Project</org_study_id>
    <nct_id>NCT04329390</nct_id>
  </id_info>
  <brief_title>MAC Project, Monitoring of AntiCoagulant Therapies (MAC)</brief_title>
  <acronym>MAC</acronym>
  <official_title>MAC Project, Monitoring of AntiCoagulant Therapies (MAC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quovadis Associazione</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Quovadis Associazione</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MAC Project is a prospective cohort, multicenter, observational, no-profit study aimed to&#xD;
      prospectively collect reliable real-life clinical information in unselected VTE or NVAF&#xD;
      patients treated with any DOAC, during a medium-long term follow-up period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MAC Project is a prospective cohort, multicenter, observational, no-profit study aimed to&#xD;
      prospectively collect reliable real-life clinical information in unselected VTE or NVAF&#xD;
      patients treated with any DOAC, during a medium-long term follow-up period. Patients will be&#xD;
      investigated in Italian hospital-based clinical centers, skilled in the management of adult&#xD;
      patients with VTE or NVAF requiring anticoagulant treatment, and followed-up up to 5 years.&#xD;
      The drugs will be prescribed according to current standards of care and regulations and not&#xD;
      provided by any sponsor. The primary outcome is to collect and evaluate the safety and&#xD;
      efficacy data of DOACs in a real-life setting, regardless of the underlying pathology, and&#xD;
      the duration of treatment. The secondary outcome is to separately evaluate safety and&#xD;
      efficacy of DOACs for treatment of cardiovascular diseases, specifically considering&#xD;
      treatment duration, as follows: short-term (e.g., superficial venous thrombosis); medium-term&#xD;
      (e.g., deep vein thrombosis, pulmonary embolism, etc.); long-term (e.g., atrial fibrillation,&#xD;
      prevention of recurrent VTE or long-term treatment of recurrent VTE, peripheral arterial&#xD;
      obstructive disease, etc.).Investigators will store event-driven clinical information into a&#xD;
      REDCap based on-line EDC system about management and outcome of all efficacy and safety&#xD;
      end-points; treatment compliance/adherence; VTE risk factors; thromboembolic and haemorrhagic&#xD;
      risk-scores; comorbidities; concomitant treatments; patients' appreciation by a specific&#xD;
      score (ACTS); clinical or adverse events; survival; possible causes of death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>SAFETY OF OAC THERAPY</measure>
    <time_frame>5 years</time_frame>
    <description>incidence of major bleeding, incidence of clinically relevant non-major bleeding, incidence of minor bleeding, incidence of serious adverse events, incidence of mortality (VTE-related, cardiovascular, and all-cause).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EFFICACY OF OAC THERAPY</measure>
    <time_frame>5 years</time_frame>
    <description>incidence of symptomatic recurrent VTE, incidence of symptomatic recurrent VTE in the various treatment subgroups, incidence of stroke (ischemic and haemorrhagic), incidence of systemic embolic events, number of hospital admissions related to cardiovascular (either venous or arterial) disease, incidence of post-thrombotic syndrome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time relate outcomes</measure>
    <time_frame>5 years</time_frame>
    <description>To separately evaluate safety and efficacy of DOACs for treatment of cardiovascular diseases, specifically considering treatment duration, as follows: short-term (e.g., superficial venous thrombosis); medium-term (e.g., deep vein thrombosis, pulmonary embolism, etc.); long-term (e.g., atrial fibrillation, prevention of recurrent VTE or long-term treatment of recurrent VTE, peripheral arterial obstructive disease, etc.).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Anticoagulants and Bleeding Disorders</condition>
  <arm_group>
    <arm_group_label>anticoagulant</arm_group_label>
    <description>Subjects of both sexes, aged 18 years or older, requiring the prescription of, or already on oral anticoagulant treatment, will be eligible for the study, irrespective of the index event, of the intended treatment duration, and the type of drug used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anticoagulant drugs</intervention_name>
    <description>Prescription of, or already on oral anticoagulant treatment.</description>
    <arm_group_label>anticoagulant</arm_group_label>
    <other_name>OAC</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Setting: clinical centers, either hospital-based or outpatient clinics, experienced in the&#xD;
        management of patients with cardiovascular diseases requiring anticoagulant treatment,&#xD;
        either on short- (e.g., superficial venous thrombosis), medium- (e.g., deep-vein&#xD;
        thrombosis, pulmonary embolism, acute coronary syndrome, etc.), and long-term (e.g., atrial&#xD;
        fibrillation, mechanic heart valves, secondary prevention of recurrent VTE, obstructive&#xD;
        arterial disease of the lower limbs, etc.).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged &gt; 18 years,&#xD;
&#xD;
          -  mandatory anticoagulant treatment&#xD;
&#xD;
          -  ability to understand the purposes of the study&#xD;
&#xD;
          -  ability to express valid informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristiano Bortoluzzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quovadis Associazione</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristiano Bortoluzzi, MD</last_name>
    <phone>+39-041763457</phone>
    <email>crisbort@libero.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giuseppe Camporese, MD</last_name>
    <phone>+39-0498212933‬</phone>
    <email>giuseppe.camporese@aopd.veneto.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Giuseppe Camporese</name>
      <address>
        <city>Padova</city>
        <zip>35138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe MD Camporese</last_name>
      <phone>‭+39 049 8212933‬</phone>
      <email>giuseppe.camporese@aopd.veneto.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anticoagulant</keyword>
  <keyword>DOAC</keyword>
  <keyword>OAC</keyword>
  <keyword>benefit-risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT04329390/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

